Bispecific antibodies vs CAR T-cell therapy
| . | Bispecific antibody . | CAR T-cell . |
|---|---|---|
| Approved product | Teclistimab | Ide-cel and Cilta-cel |
| Efficacy | +++ | ++++ |
| CRS | ++ | +++ |
| Neurotoxicity | + | ++ |
| Infections | +++ | +++ |
| How given | IC/SC every 1-4 weeks continuous | Only once |
| Availability | Off-the-shelf | Limited |
| Need for bridging | No | Often |
| Where given | Specialized center, Community possible | Specialized center |
| Unfit patient | Possible | Challenging |
| . | Bispecific antibody . | CAR T-cell . |
|---|---|---|
| Approved product | Teclistimab | Ide-cel and Cilta-cel |
| Efficacy | +++ | ++++ |
| CRS | ++ | +++ |
| Neurotoxicity | + | ++ |
| Infections | +++ | +++ |
| How given | IC/SC every 1-4 weeks continuous | Only once |
| Availability | Off-the-shelf | Limited |
| Need for bridging | No | Often |
| Where given | Specialized center, Community possible | Specialized center |
| Unfit patient | Possible | Challenging |
CAR, chimeric antigen receptor; CRS, cytokine release syndrome; IV, intravenous; SQ, subcutaneous.